<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Melo, A.</style></author><author><style face="normal" font="default" size="100%">Kokras, N</style></author><author><style face="normal" font="default" size="100%">Dalla, C</style></author><author><style face="normal" font="default" size="100%">Ferreira, C</style></author><author><style face="normal" font="default" size="100%">Ventura-Silva, A P</style></author><author><style face="normal" font="default" size="100%">Sousa, N.</style></author><author><style face="normal" font="default" size="100%">Pêgo, J M</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The positive effect on ketamine as a priming adjuvant in antidepressant treatment.</style></title><secondary-title><style face="normal" font="default" size="100%">Transl Psychiatry</style></secondary-title><alt-title><style face="normal" font="default" size="100%">Transl Psychiatry</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Antidepressive Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">anxiety</style></keyword><keyword><style  face="normal" font="default" size="100%">aspartic acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Behavior, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Brain</style></keyword><keyword><style  face="normal" font="default" size="100%">Depression</style></keyword><keyword><style  face="normal" font="default" size="100%">Depressive Disorder, Major</style></keyword><keyword><style  face="normal" font="default" size="100%">Disease Models, Animal</style></keyword><keyword><style  face="normal" font="default" size="100%">Drug Therapy, Combination</style></keyword><keyword><style  face="normal" font="default" size="100%">Fluoxetine</style></keyword><keyword><style  face="normal" font="default" size="100%">glutamic acid</style></keyword><keyword><style  face="normal" font="default" size="100%">Imipramine</style></keyword><keyword><style  face="normal" font="default" size="100%">Ketamine</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Prefrontal Cortex</style></keyword><keyword><style  face="normal" font="default" size="100%">Pyramidal Cells</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats</style></keyword><keyword><style  face="normal" font="default" size="100%">Rats, Wistar</style></keyword><keyword><style  face="normal" font="default" size="100%">Stress, Psychological</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015 May 26</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">5</style></volume><pages><style face="normal" font="default" size="100%">e573</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Ketamine is an anesthetic with antidepressant properties. The rapid and lasting effect of ketamine observed in preclinical and clinical research makes it a promising therapeutic to improve current major depression (MD) treatment. Our work intended to evaluate whether the combined use of classic antidepressants (imipramine or fluoxetine) and ketamine would improve the antidepressant response. Using an animal model of depressive-like behavior, we show that the addition of ketamine to antidepressants anticipates the behavioral response and accelerates the neuroplastic events when compared with the use of antidepressants alone. In conclusion, our results suggest the need for a reappraisal of the current pharmacological treatment of MD. </style></abstract><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/26080090?dopt=Abstract</style></custom1></record></records></xml>